Skip to main content
Clinical Trials/NCT06793059
NCT06793059RecruitingNot Applicable

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

Jacobs institute1 site in 1 country10 target enrollmentStarted: January 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
10
Locations
1
Primary Endpoint
Occurrence of thromboembolic event(s)

Study Overview

Brief Summary

The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms

Detailed Description

The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio < 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
22 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments.

Exclusion Criteria

  • •Exclusion Criteria:
  • •Cannot provide consent or legally authorized representative not available to provide consent Criteria:

Arms & Interventions

SHIELD Study Arm

Other

Active treatment with the Pipeline SHIELD Device

Intervention: SHIELD (Device)

Outcomes

Primary Outcomes

Occurrence of thromboembolic event(s)

Time Frame: 12 Months

The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Jacobs institute
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Elad Levy

Principal Investigator

Jacobs institute

Study Sites (1)

Loading locations...

Similar Trials